{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-016231","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.950180+00:00","generated_at":"2026-06-22T08:11:35.588932+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Collegium Q3 record revenue $127M (+61% YoY), adj. EPS $1.10, raises FY guidance; completes Xtampza ER renegotiation","bullets":["Record Q3 revenue $127.0M (+61% YoY); GAAP net income $0.5M ($0.01 EPS), adj. net income $42.5M ($1.10 adj. EPS).","Completed Xtampza ER contract renegotiations; gross-to-net <65% effective Jan 1, 2023, maintaining broad access.","Returned $10M capital via share repurchases ($6.4M in Q3, $3.6M in Oct). $42.1M remains under $100M program.","Updated FY2022 guidance: revenue $455-465M, adj. EBITDA $250-255M, adj. opex $125-130M.","Ended Q3 with $134.1M cash; made $25M debt repayments; BDSI synergy target raised to ~$85M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-016231","json":"https://secwatch.observer/filing/0001558370-22-016231.json","markdown":"https://secwatch.observer/filing/0001558370-22-016231.md","text":"https://secwatch.observer/filing/0001558370-22-016231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000155837022016231/0001558370-22-016231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000155837022016231/coll-20221103x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:11:35.588932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81f64d0b87062bacdc6a0248189dd8910430fb6c","claim":"COLLEGIUM PHARMACEUTICAL, INC reported quarter ended September 30, 2022 results: revenue 127.0 million, net income 0.5 million, EPS 0.01.","evidence_excerpt":"Total net product revenues were $127.0 million for the quarter ended September 30, 2022 (the “2022 Quarter”), compared to $78.8 million for the quarter ended September 30, 2021 (the “2021 Quarter”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837022016231/0001558370-22-016231-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Revenue","value":"127.0 million"},{"label":"Net income","value":"0.5 million"},{"label":"EPS","value":"0.01"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}